MedTrace Logo

Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study

NCT03650127 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3449

Last updated 2021-01-15

No results posted yet for this study

Summary

P5.fi study - P4 together with a fifth 'P' and '.fi' for population health Finally Implemented in Finland - studies the value of returning genetic and metabolomic risk information in two diseases (coronary heart disease and type 2 diabetes) and one feature (venous thromboembolism). The hypothesis of the study is that 1) combining genetic and metabolic risk with traditional risk factors adds value to the personal risk assessment of these diseases, 2) such risk information can be provided to individuals using a web based user portal in an easily understandable and useful format, and 3) receiving genetic and metabolomic risk information has an effect on the health of the study participants.

The study is a continuation of FinHealth 2017 -study, which involved more than 7,000 Finns from around the country. The participants of FinHealth were invited to participate in P5.fi -study. The new research utilises information, samples, and measurements obtained in the FinHealth Study. Prospective clinical significance of selected genetic and metabolomic risk scores will be studied in 30.000 Finnish individuals. The study will analyze the genetic and metabolomic profile of the P5.fi participants and develop and test a protocol for returning them health related risk information. The impact of the intervention will by followed up by questionnaires and national health registers for five years.

Conditions

Sponsors & Collaborators

  • University of Helsinki

    collaborator OTHER

  • Institute for Molecular Medicine

    collaborator OTHER

  • Markus Perola

    lead OTHER_GOV

Principal Investigators

  • Markus Perola, MD, PhD · National Institute of Health and Welfare

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-02
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03650127 on ClinicalTrials.gov